Why Is Shattuck Labs (STTK) Stock Up 93% Today?
Shattuck Labs (NASDAQ:STTK) stock is on the rise Wednesday after the clinical-stage biotechnology company announced results from an ongoing Phase 1a/b trial. These clinical trials cover the use of SL-172154 in combination with azacitidine in HR-MDS and TP53m Acute Myeloid Leukemia (AML) patients.…#shattucklabs #phase1a #acutemyeloidleukemia #aml #linipandite #sttk #palantirtechnologies #pltr #reshapelifesciences #williamwhite (Source: Reuters: Health)
Source: Reuters: Health - December 13, 2023 Category: Consumer Health News Source Type: news
ASH: MRD-Directed Ibrutinib-Venetoclax Treatment Beneficial in Leukemia
WEDNESDAY, Dec. 13, 2023 -- For patients with chronic lymphocytic leukemia (CLL), measurable residual disease (MRD)-directed ibrutinib-venetoclax treatment improves progression-free and overall survival, according to a study published online Dec.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 13, 2023 Category: Pharmaceuticals Source Type: news
Measurable Residual Disease-Guided Therapy Promising in CLL Measurable Residual Disease-Guided Therapy Promising in CLL
The ibrutinib-venetoclax combination was particularly effective in patients with chronic lymphocytic leukemia with high-risk features such as IGHV unmutated disease or chromosomal abnormalities.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia
(MedPage Today) -- SAN DIEGO -- Nearly two-thirds of patients with relapsed or refractory KMT2A-rearranged acute leukemia responded to an investigational oral menin inhibitor, a phase II trial showed.
Among 57 children and adults in the pivotal... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 12, 2023 Category: Hematology Source Type: news
MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemia
(MedPage Today) -- SAN DIEGO -- Measurable residual disease (MRD) after induction therapy can guide the use of allogeneic transplant in patients with NPM1-mutated acute myeloid leukemia (AML) in first remission, regardless of whether FLT3 internal... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 11, 2023 Category: Hematology Source Type: news
'New Gold Standard' for Previously Untreated CLL
(MedPage Today) -- SAN DIEGO -- A time-limited, targeted combination significantly improved survival compared with chemoimmunotherapy in fit chronic lymphocytic leukemia (CLL) patients who met criteria for starting treatment, findings from the... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 10, 2023 Category: Hematology Source Type: news
Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients
(MedPage Today) -- SAN DIEGO -- A time-limited, targeted combination significantly improved survival compared with chemoimmunotherapy in fit chronic lymphocytic leukemia (CLL) patients who met criteria for starting treatment, findings from the... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 10, 2023 Category: Hematology Source Type: news
Completely Oral Regimen Effective, Feasible in APL
(MedPage Today) -- SAN DIEGO -- An all-oral regimen for newly diagnosed acute promyelocytic leukemia (APL) proved "highly effective and safe," with most patients avoiding chemotherapy altogether, a researcher reported here.
In a multicenter... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 10, 2023 Category: Hematology Source Type: news
Servier Showcases Leadership in Mutant Isocitrate Dehydrogenase (IDH) Inhibition Through New Data Spotlighting Real-World Treatment Patterns and Clinical Outcomes of Tibsovo ® Use at ASH 2023
Learn more about Servier's leadership in mutant IDH inhibition at ASH booth #1347 BOSTON, Dec. 9, 2023 /PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, will be presenting new data in acute myeloid leukemia (AML) at the... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 9, 2023 Category: Pharmaceuticals Tags: TRI TDS Source Type: news
US drug shortages hit record high and lawmakers warn they could mean 'life or death for MILLIONS of patients' - as girl, 9, with leukemia faces 15-MONTH wait for lifesaving medication that costs just $10
Laura Bray, a mom from Florida, learned of the drug shortage first-hand when her daughter (left) was diagnosed with leukemia and the hospital ran out of the $10 drug she needed for treatment. (Source: the Mail online | Health)
Source: the Mail online | Health - December 7, 2023 Category: Consumer Health News Source Type: news
Girl, 9, with leukemia faces 15 MONTH wait for lifesaving $10 drug as US cancer and asthma medicine shortages hit record high - aw lawmakers warn it could mean 'life or death for MILLIONS of patients'
Laura Bray, a mom from Florida, learned of the drug shortage first-hand when her daughter was diagnosed with leukemia and the hospital ran out of the $10 drug she needed for treatment. (Source: the Mail online | Health)
Source: the Mail online | Health - December 7, 2023 Category: Consumer Health News Source Type: news
Girl, 2, dies after catching rare virus from a PIGEON - and doctors don't know how she got infected
Medics still don't know how the two-year-old, who was battling leukaemia, caught the highly contagious virus. But they think she might have got infected by touching pigeon faeces or fluids. (Source: the Mail online | Health)
Source: the Mail online | Health - December 7, 2023 Category: Consumer Health News Source Type: news
Non-Covalent BTK Inhibitor Approved for CLL
(MedPage Today) -- The FDA expanded the label of pirtobrutinib (Jaypirca) to include the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) following two prior lines of therapy, the agency announced on Friday.
An... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 4, 2023 Category: Hematology Source Type: news
Charting the Course: From Young Adult Leukemia Patient to Oncologist
(MedPage Today) -- "Would you like to have a bone marrow biopsy today or tomorrow?" These are the only words I remember coming from the oncologist who I had just met in the emergency department (ED).
I was in my second year of medical school and... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 3, 2023 Category: Hematology Source Type: news
Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor
The first and only non-covalent (reversible) BTK inhibitor, Jaypirca has been shown to extend the benefit of BTK inhibition
In the BRUIN Phase 1/2 trial, adult patients with CLL/SLL who have received at least two lines of therapy, including a BTK... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 1, 2023 Category: Drugs & Pharmacology Source Type: news
